samedan logo

 
 
spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

New IATA Guidance Prepares for Global Vaccine Distribution

IATA (International Air Transport Association)




Geneva - The International Air Transport Association (IATA) released guidance to ensure that the air cargo industry is ready to support the large-scale handling, transport and distribution of a COVID-19 vaccine. IATA’s Guidance for Vaccine and Pharmaceutical Logistics and Distribution provides recommendations for governments and the logistics supply chain in preparation for what will be the largest and most complex global logistics operation ever undertaken.

Reflecting the complexity of the challenge, the Guidance was produced with the support of a broad range of partners, including the International Civil Aviation Organization (ICAO), International Federation of Freight Forwarders Associations (FIATA), International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Pan American Health Organization (PAHO) , UK Civil Aviation Authority, World Bank, World Customs Organization (WCO) and World Trade Organization (WTO). The guidance includes a repository of international standards and guidelines related to the transport of vaccines and will be updated regularly as information is made available to the industry. Accompanying the guidance, IATA established a joint information-sharing forum for stakeholders.

“Delivering billions of doses of a vaccine that must be transported and stored in a deep-frozen state to the entire world efficiently will involve hugely complex logistical challenges across the supply chain. While the immediate challenge is the implementation of COVID-19 testing measures to re-open borders without quarantine, we must be prepared for when a vaccine is ready. This guidance material is an important part of those preparations,” said IATA’s Director General and CEO, Alexandre de Juniac.

Key challenges addressed in IATA’s Guidance for Vaccine and Pharmaceutical Logistics and Distribution include:

  • The availability of temperature-controlled storage facilities and contingencies when such facilities are not available

  • Defining roles and responsibilities of parties involved in the distribution of vaccines, particularly government authorities and NGOs, to assist safe, fast and equitable distribution as broadly as possible

Industry preparedness for vaccine distribution which includes:

  • Capacity & Connectivity: The global route network has been reduced dramatically from the pre-COVID 22,000 city pairs. Governments need to re-establish air connectivity to ensure adequate capacity is available for vaccine distribution.

  • Facilities and infrastructure: The first vaccine manufacturer to apply for regulatory approval requires the vaccine to be shipped and stored in a deep-frozen state, making ultra-cold chain facilities across the supply chain essential. Some types of refrigerants are classified as a dangerous goods and volumes are regulated which adds an additional layer of complexity. Considerations include availability of temperature-controlled facilities and equipment and staff trained to handle time- and temperature-sensitive vaccines.

  • Border management: Timely regulatory approvals and storage and clearance by customs and health authorities will be essential. Priorities for border processes include introducing fast-track procedures for overflight and landing permits for operations carrying the COVID-19 vaccine and potential tariff relief to facilitate the movement of the vaccine.

  • Security: Vaccines are highly valuable commodities. Arrangements must be in place to ensure that shipments remain secure from tampering and theft. Processes are in place already, but the huge volume of vaccine shipments will require early planning to ensure that they are scalable.
phone +1 786-536-1667
web https://www.iata.org/
email 800 Place Victoria PO Box 113 Montreal - H4Z 1M1 Quebec - Canada
 
Print this page
Send to a friend
   
spacer
News and Press Releases

PTC Therapeutics Reports the Initiation of the Second Stage of the FITE19 Phase 2/3 Clinical Trial Evaluating PTC299 for the Treatment of COVID-19

PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced the initiation of the second stage of the FITE19 clinical trial to assess PTC299 in COVID-19 patients. PTC299 is an oral investigational drug with a novel dual mechanism of action that has the potential to inhibit viral replication and attenuate the uncontrolled inflammatory response that ensues after infection.
More info >>


White Papers

Delivering Fit For Purpose Biomanufacturing CHO Cell Lines

Fujifilm Diosynth Biotechnologies

The challenge during mammalian cell line development is to identify and isolate stable, high expressing cell lines producing product with the appropriate critical product quality attributes rapidly, reproducibly and with relative ease. Obtaining a host cell line that inherently exhibits desirable biomanufacturing attributes can therefore have a significantly positive effect on the identification of recombinant cell lines with desired traits during cell line development screens. In this study, we demonstrate that it is possible to exploit intrinsic heterogeneity within host cell populations and identify host cell lines which are more “fit for purpose”.
More info >>

Industry Events

DIA Europe 2021

15-19 March 2021, VIRTUAL CONFERENCE

DIA Europe is the must-attend event for all life science professionals working in drug development, from discovery to marketed use. It encourages open collaboration by bringing together representatives from the entire spectrum of the life science landscape and facilitating crucial discussions across several topic tracks: Clinical Development, Regulatory Strategy, Pharmacovigilance, Value and Access, Health Policy, and many more.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement